HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Acute type A viral hepatitis — Clinical Guidelines

Overview

Acute type A viral hepatitis, primarily caused by Hepatitis A Virus (HAV), is characterized by acute liver inflammation leading to symptoms such as jaundice, fatigue, and abdominal pain. It can present atypically, especially in children, with complications like cholestasis, ascites, and thrombocytopenia 2.

Diagnosis

Clinical Criteria: Acute onset of symptoms including jaundice, nausea, and abdominal pain 1 7.

Laboratory Tests: Positive IgM anti-HAV antibodies 1 2 3.

Rapid Diagnostic Tests: Useful for outbreaks but less reliable in low prevalence settings (sensitivity 66-86%, specificity 21-100%) 3.

Molecular Diagnostics: PCR amplification for HAV RNA confirmation 4 14.

Management

Supportive Care: Includes hydration, rest, and management of symptoms 1 7.

No Specific Antiviral Treatment: No antiviral therapy is recommended for acute HAV infection 1 2 3.

Monitoring: Regular monitoring of liver function tests and clinical status 1 14.

Special Populations

Children: Atypical manifestations such as prolonged cholestasis and ascites are noted, requiring close monitoring 2.

Comorbidities: No specific comorbidities highlighted in abstracts; general supportive care applies 1 7.

Key Recommendations

Prompt Diagnosis: Early diagnosis through clinical presentation combined with detection of IgM anti-HAV antibodies is crucial for timely management 1 2. (Evidence: Strong)

Avoid Specific Antiviral Therapy: No specific antiviral treatment is indicated for acute HAV infection; focus on supportive care 1 2 3. (Evidence: Strong)

Monitor for Complications: Especially in children, monitor for atypical manifestations like prolonged cholestasis and ascites, which may indicate more complex disease courses 2. (Evidence: Moderate)

Note: Recommendations vary regarding atypical presentations and their management 2 5.

References

1 Verma HK, Prasad K, Kumar P, Lvks B. Viral hepatitis: A global burden needs future directions for the management. World journal of gastroenterology 2022. link 2 Alam R, Karim ASMB, Mazumder MW, Das SR, Benzamin M, Sonia ZF et al.. Atypical manifestations of acute viral hepatitis A in children in Bangladesh: Are these really uncommon?. Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology 2021. link 3 de Almeida Ribeiro CR, Amado LA, Tourinho RS, Pinto Lima LR, Melgaço JG, de Almeida AJ et al.. Accuracy of rapid test for diagnosis of hepatitis A with different infection rate settings and with predictive modeling. Future microbiology 2019. link 4 Ruchusatsawat K, Wongpiyabovorn J, Kawidam C, Thiemsing L, Sangkitporn S, Yoshizaki S et al.. An Outbreak of Acute Hepatitis Caused by Genotype IB Hepatitis A Viruses Contaminating the Water Supply in Thailand. Intervirology 2016. link 5 Cao J, Bi S, Meng Q, Shen L, Zheng H, Zhang Y. Genotyping of acute hepatitis a virus isolates from China, 2003-2008. Journal of medical virology 2011. link 6 Jothikumar N, Cromeans TL, Sobsey MD, Robertson BH. Development and evaluation of a broadly reactive TaqMan assay for rapid detection of hepatitis A virus. Applied and environmental microbiology 2005. link 7 Poddar U, Thapa BR, Prasad A, Singh K. Changing spectrum of sporadic acute viral hepatitis in Indian children. Journal of tropical pediatrics 2002. link 8 Raychaudhuri G, Govindarajan S, Shapiro M, Purcell RH, Emerson SU. Utilization of chimeras between human (HM-175) and simian (AGM-27) strains of hepatitis A virus to study the molecular basis of virulence. Journal of virology 1998. link 9 Leung NW. Patterns of viral hepatitis in Hong Kong. British journal of hospital medicine 1997. link 10 Emerson SU, Tsarev SA, Govindarajan S, Shapiro M, Purcell RH. A simian strain of hepatitis A virus, AGM-27, functions as an attenuated vaccine for chimpanzees. The Journal of infectious diseases 1996. link 11 Inoue K, Yoshiba M, Yotsuyanagi H, Otsuka T, Sekiyama K, Fujita R. Chronic hepatitis A with persistent viral replication. Journal of medical virology 1996. link1096-9071(199612)50:4<322::AID-JMV7>3.0.CO;2-A) 12 Wilairatana P. Acute viral hepatitis A: a cause of jaundice in typhoid fever. The Southeast Asian journal of tropical medicine and public health 1996. link 13 Torre D, Zeroli C, Giola M, Ferrario G, Fiori GP, Bonetta G et al.. Serum levels of interleukin-1 alpha, interleukin-1 beta, interleukin-6, and tumor necrosis factor in patients with acute viral hepatitis. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1994. link 14 Okuno T, Shindo M, Arai K, Matsumoto M, Takeda M, Kashima K et al.. Detection of 2',5' oligoadenylate synthetase activity in acute viral hepatitis with special reference to histologic features in the acute stage. Gastroenterologia Japonica 1991. link 15 Braito A, Cellesi C, Fanti O, Civitelli F, Fanetti G, Almi P. Impact of hepatitis A in Siena: a "traveller's disease"?. European journal of epidemiology 1990. link 16 Atono Y, Sata M, Tanikawa K. Kinetics of C-reactive protein in acute viral hepatitis. Gastroenterologia Japonica 1989. link 17 Aronson NE, Palmer BF. Acute viral hepatitis in American soldiers in Korea. Southern medical journal 1988. link 18 Masuda T, Satodate R, Suzuki K, Sato S. Nuclear deformity of hepatocytes in acute viral hepatitis. The Tohoku journal of experimental medicine 1988. link 19 Wiedmann KH, Brattig NW, Diao GD, Schomerus H, Dölle W, Berg PA. Serum inhibitory factors (SIF) are of prognostic value in acute viral hepatitis. Lancet (London, England) 1985. link91083-9) 20 Manca F, Cauda R, Laghi V, Cantarella S, Trovatello G, Ortona L et al.. Follow-up of circulating immune complexes in the course of acute viral hepatitis, and correlation with serologically relevant parameters. Hepato-gastroenterology 1984. link 21 Kryger P, Christoffersen P. Liver histopathology of the hepatitis A virus infection: a comparison with hepatitis type B and non-a, non-b. Journal of clinical pathology 1983. link 22 Govindarajan S, Uchida T, Peters RL. Identification of T lymphocytes and subsets in liver biopsy cores of acute viral hepatitis. Liver 1983. link 23 Papaevangelou G, Roumeliotou-Karayannis A, Contoyannis P. Changing epidemiological characteristics of acute viral hepatitis in Greece. Infection 1982. link 24 Bortolotti F, Cadrobbi P, Carretta M, Meneghetti F, Pornaro E, Realdi G. Epidemiological aspects on acute viral hepatitis in northern Italy. Scandinavian journal of infectious diseases 1982. link 25 Barker LF, Dienstag JL, Lorenz DE, Purcell RH, Wong DC, Feinstone SM et al.. Serologic and animal inoculation studies of a communal outbreak of viral hepatitis, type A. The American journal of the medical sciences 1977. link 26 Dienstag JL, Gust ID, Lucas CR, Wong DC, Purcell RH. Mussel-associated viral hepatitis, type A: serological confirmation. Lancet (London, England) 1976. link90358-5)